Navigation Links
Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)
Date:5/31/2008

- Results Confirm Previously Demonstrated Survival Advantages of Tarceva in

This Difficult-to-Treat Disease

- ABSTRACT No: 4507

BASEL, Switzerland, May 31 /PRNewswire/ -- Adding Avastin (bevacizumab) to a combination of Tarceva (erlotinib) and chemotherapy significantly improves the time patients with metastatic pancreatic cancer live without their disease getting worse ("progression free survival"). These data, presented for the first time today at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, also showed a trend towards extending life expectancy.

Pancreatic cancer is the sixth leading cause of cancer death in Europe(1) and is extremely difficult to treat because it spreads rapidly to other parts of the body and often shows resistance to chemotherapy and radiotherapy(2). It is also difficult to diagnose, with no effective early diagnostic test available(3) so the majority of patients are diagnosed with advanced disease.

"For patients with advanced pancreatic cancer, the treatment options are limited," commented Professor Eric Van Cutsem, Professor of Medicine, Gastrointestinal Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. "The interesting results show the need for further exploring which patients benefit from the combination of gemcitabine plus Avastin and Tarceva in view of the statistically longer PFS which trends towards improved survival."

The results of the phase III AVITA (BO17706) study showed that the addition of Avastin to a Tarceva/gemcitabine combination resulted in:

- A 37% increase in the time patients live without their disease getting

worse compared to Tarceva/gemcitabine alone

- Almost 14% of patients experiencing a complete disappearance or

shrinkage of their tumor

- A trend towards improved overall survival

- No new safety signals for Avastin

In addition, data from the Tarceva/gemcitabine control arm were consistent with previous results from the PA3 study, reinforcing the already established survival benefits of Tarceva in pancreatic cancer(4).

About AVITA

The AVITA (BO17706) study is a Roche-sponsored, randomized, double-blind, placebo-controlled phase III study that included 607 patients with metastatic pancreatic cancer. Study participants received first-line treatment with either gemcitabine, Tarceva and placebo or gemcitabine, Tarceva and Avastin (at 5mg/kg every two weeks).

The AVITA study did not meet its primary endpoint of overall survival (OS), however results showed that adding Avastin to a combination of Tarceva and chemotherapy significantly improved the time patients with pancreatic cancer lived without their disease getting worse (PFS). A trend towards improved OS was also observed.

In addition, the findings in the gemcitabine/Tarceva control arm of this trial were consistent with the efficacy observed in the metastatic patient population in the pivotal Phase III PA3 study led to the regulatory approval of Tarceva for the treatment of pancreatic cancer in the US in 2005 and in the EU in 2007.

Additional information

- Roche in Oncology:

http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf

- Roche Health Kiosk, Cancer: http://www.health-kiosk.ch/start_krebs

- Avastin: http://www.avastin-info.com

To access video clips about Avastin in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com .

References

(1). Michaud. Minerva Chir, 2004; 59: 99-111.

(2). Khosravi Shahi. Anales de Medicina Interna, 2005; 22: 390-4.

(3). Stewart. et al. World Health Organisation and the International

Agency for Research on Cancer, IARC Press/Lyon, 248-9.

(4). Moore et al. J Clin Oncol, 2007; 25: 1960-6.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
2. New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
3. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
4. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
5. Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
6. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
7. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
8. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
9. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
10. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
11. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 3% as currency reduced sales growth ... per diluted share as reported (EPS) were $4.44, compared ... was $4.65, an increase of 10% over the prior-year ...
(Date:2/4/2016)... Md. , Feb. 4, 2016 In response ... , the FDA,s Deputy Commissioner for Medical Products and Tobacco, ... plan to reassess the agency,s approach to opioid medications. The ... while still providing patients in pain access to effective relief. ... FDA will: , Re-examine the risk-benefit paradigm for ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... With the FCPX LUT: Summer pack from Pixel ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. By manipulating each pixel, LUT's can change each color range differently, it gives ...
(Date:2/5/2016)... ... ... Love is in the air at King Kullen! The local grocer is offering ... for Valentine’s Day is a must-have, and can be picked up with all other ... long-stem roses available, but also other flower bouquets, elegantly wrapped and ready to go. ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University ... Allen have signed a joint enrollment and degree completion agreement. The agreement, ... and baccalaureate degrees at FHU|Dickson. , The agreement allows students to be ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
Breaking Medicine News(10 mins):